Abstract
BackgroundFamily with sequence similarity 65 member A (FAM65A), also known as RIPOR1, is differentially expressed between human tumor and non-tumor tissues in kinds of cancers. In addition, it was reported that the product of FAM65A may be a biomarker for cholangiocarcinoma patients. However, there is still no evidence on the relationship between the FAM65A and different types of tumors. Our study is mainly for exploring the prognostic values of FAM65A in pan-cancer and for further discovering a potential therapeutics target.MethodsWe analyzed FAM65A expression, prognostic values, genetic alteration, protein phosphorylation, immune infiltration and enrichment analysis across different types of human malignant tumors based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Additionally, Real-Time PCR (RT-qPCR) was performed to further confirm the roles of FAM65A in the pathogenesis of colorectal cancer.ResultsWe found that FAM65A expression was associated with the prognosis of multiple human tumors, especially colorectal cancer. Moreover, we also observed that FAM65A was highly expressed in colorectal cancer through RT-qPCR. We observed that decreasing phosphorylation level of the S351 locus in colon adenocarcinoma, uterine corpus endometrial carcinoma and lung adenocarcinoma. And the expression of FAM65A was positively related to cancer-associated fibroblasts (CAFs) infiltration in many tumors, such as colon adenocarcinoma. Therefore, FAM65A may be a potential prognostic biomarker of human tumors.
Highlights
With sequence similarity 65 member A (FAM65A), known as RHO family interacting cell polarization regulator 1 (RIPOR1), is differentially expressed between human tumor and non-tumor tissues in kinds of cancers
We found that Family with sequence similarity 65 member A (FAM65A) expression levels in tumor tissue of cholangio carcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), hepatocellular carcinoma (LIHC), colon adenocarcinoma (COAD), pheochromocytoma and paraganglioma (PCPG) and stomach adenocarcinoma (STAD) are higher than the corresponding normal tissue based on The Cancer Genome Atlas (TCGA) dataset (Fig. 1a)
FAM65A expression levels in tumor tissue of breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), uterine corpus endometrial carcinoma (UCEC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC) and Pancreatic adenocarcinoma (PAAD) are lower than the corresponding normal tissue based on TCGA dataset (Fig. 1a)
Summary
With sequence similarity 65 member A (FAM65A), known as RIPOR1, is differentially expressed between human tumor and non-tumor tissues in kinds of cancers. Methods We analyzed FAM65A expression, prognostic values, genetic alteration, protein phosphorylation, immune infiltration and enrichment analysis across different types of human malignant tumors based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Results We found that FAM65A expression was associated with the prognosis of multiple human tumors, especially colorectal cancer. We observed that FAM65A was highly expressed in colorectal cancer through RT-qPCR. FAM65A may be a potential prognostic biomarker of human tumors. Due to the complexity and stealthiness of the form and development of tumors, most patients don’t receive timely treatment, and resulting in poor prognosis. Pan-cancer analysis is valuable to reveal the correlation between any gene of interest and its clinical prognosis as well as its potential molecular mechanisms across different tumors [2]. TCGA Pan-Cancer analysis project, which is funded by USA National Institutes of health, includes functional genomics data in different tumors and provides the possibility for us to perform pan-cancer analysis [4,5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
